% 0期刊文章% Nikos Gorgoraptis %一个李卢西亚%亚历克斯·惠廷顿%琳达麦克莱恩%一个伊万·罗斯克莱尔·麦克劳德% % Jan Passchier卡尔·A·齐默尔曼% %保罗·m·马修斯%一个汤姆·m·麦克米兰罗杰·N·甘恩% % David J .急剧% T [18 f] av - 1451正电子发射断层扫描显示τ病理学在长期创伤性脑损伤的幸存者(S9.007) % D J神经病学2017% % P S9.007 X % V % 88% N 16补充目的:评估τ病理学单事件后创伤性脑损伤(TBI)使用[18 f] av - 1451正电子发射断层扫描(PET)和检查它与脑萎缩的关系,认知能力和临床结果。首页背景:创伤性脑损伤是神经细胞退化和痴呆的一个危险因素如慢性创伤性脑病。广泛τ病理学是事后剖析长期单事件创伤性脑损伤的幸存者,但对τ病理学在活体内的分布。设计/方法:27个参与者,包括17个创伤性脑损伤的患者(11个可怜的结果,6好结果)和10个健康对照组),类似于年龄和社会经济背景评估的三组之一:我)贫穷或恶化的临床结果,2)良好的临床结果,和iii)健康志愿者。纵向评估超过18年使用格拉斯哥结果Scale-Extended(戈斯)定义病人的结果。参与者接受[18 f] av - 1451宠物,磁共振成像(MRI)和神经心理测试。绑定潜在(BPND) 18 f av - 1451生产的图像使用SRTM中实现MIAKAT™软件包(www.miakat.org)。Voxelwise组差异BPND评估患者和控制之间的关系。患者分层tau-positive或负基于个人BPND z分数地图与健康对照组相比。τ的关系状态与MRI皮质措施,认知得分和临床检查结果。结果:[18 f] av - 1451 BPND明显高于在创伤性脑损伤患者和健康志愿者相比,增加了绑定顶叶、孤立和内侧颞皮层(P < 0.05)纠正。 Tau uptake was not significantly different between good and poor outcome TBI patients. Tau-positive patients showed reduced hippocampal volumes (t=2.77, P=0.013) and were impaired on memory recall (t=2.32, P=0.032) when compared to healthy controls.Conclusions: [18F]AV-1451 PET imaging revealed increased tau binding in a proportion of individuals several years after TBI relative to matched healthy volunteers. Tau positivity was associated with relative hippocampal atrophy and reduced memory performance.Study Supported by:Medical Research Council (MRC) UKNational Institute of Health Research (NIHR) UKAvid RadiopharmaceuticalsDisclosure: Dr. Gorgoraptis has nothing to disclose. Dr. Li has nothing to disclose. Dr. Whittington has nothing to disclose. Dr. Mclean has nothing to disclose. Dr. McLeod has nothing to disclose. Dr. Ross has nothing to disclose. Dr. Zimmerman has nothing to disclose. Dr. Passchier has nothing to disclose. Dr. Matthews has received personal compensation for activities with Biogen, Novartis, Ixico, transparency Life Sciences, and Adelphi Communications. Dr. Matthews has received research support from GlaxoSmithKline and Biogen. Dr. Gunn has received personal compensation from GlaxoSmithKline, Abbvie, UCB Pharma and ITI as a consultant. Dr. McMillan has nothing to disclose. Dr. Sharp has nothing to disclose. %U